Welcome to our dedicated page for Provectus Biopha news (Ticker: PVCT), a resource for investors and traders seeking the latest updates and insights on Provectus Biopha stock.
Provectus Biopharmaceuticals develops clinical-stage immunotherapy medicines built around rose bengal sodium, a synthetic small molecule in the halogenated xanthene family. News about PVCT centers on its PV-10 and PV-305 formulations, research publications, preclinical disease models, and clinical-program activity across oncology, dermatology, and ophthalmology.
Recurring updates also cover VisiRose, the company’s ocular-therapeutics subsidiary, and rose bengal photodynamic antimicrobial therapy for infectious keratitis and other eye infections. Additional company announcements address proof-of-concept work in wound healing, infectious disease, tissue repair, hematology, and vaccine-adjuvant research, along with annual-meeting and other public-company governance matters.
Provectus (OTCQB: PVCT) announced it will not pursue the reverse stock split and share reduction approved by stockholders by December 31, 2022. The Board of Directors concluded that undertaking these measures is not in the best interests of shareholders at this time, though they expect to seek similar authority in 2023. Provectus is focused on developing immunotherapy medicines utilizing its proprietary rose bengal sodium (RBS) for various diseases and has been recognized for its high purity RBS formulation.
Provectus presented promising results from its ongoing Phase 1b/2 study of PV-10 and Keytruda for treating Stage III cutaneous melanoma at Melanoma Bridge 2022. Highlights include a 50% complete response rate (3/6 patients) and an 83% overall response rate (5/6 patients). Rapid complete responses were observed within 15 to 27 weeks. The study reported an 83% progression-free survival rate and a 100% overall survival rate for complete responders after 18 to 36 months. The findings suggest significant potential for the combination therapy, with plans for a Phase 2/3 trial in 2023.
Provectus (OTCQB: PVCT) announced the presentation of data from its ongoing Phase 1b/2 study combining PV-10 immunotherapy with KEYTRUDA for Stage III cutaneous melanoma. This presentation will occur at Melanoma Bridge 2022 in Naples, Italy, from December 1-3, 2022. The accepted abstract, titled “Response for combination of PV-10 autolytic immunotherapy and immune checkpoint blockade in stage III cutaneous melanoma,” will be delivered as a video oral communication and poster.
Provectus (OTCQB: PVCT) announced that the World Health Organization's INN Expert Committee has selected "rose bengal sodium" as the official nonproprietary name for its active pharmaceutical ingredient. This designation follows a public consultation and signifies a step towards enhanced regulatory oversight. Provectus claims to be the first to produce pharmaceutical-grade RBS with nearly 100% purity, utilizing a patented commercial-scale synthesis process. The company views this milestone as crucial for advancing its clinical development and drug discovery programs.
Provectus (OTCQB: PVCT) has expanded its research program with Dr. James G. Krueger to study PH-10, a topical drug aimed at treating inflammatory skin diseases and possibly skin neoplasms. The company has already treated over 200 patients with PH-10 in clinical trials for conditions like psoriasis and atopic dermatitis. The new research will focus on the drug's effects on human keratinocytes and its interaction with blood leukocytes, potentially improving treatment outcomes. The Krueger team previously identified significant gene expression changes associated with PH-10 treatment.
Provectus (PVCT) has launched a sponsored research program at the University of Texas Medical Branch to investigate the effects of its proprietary rose bengal sodium (RBS) on wound healing. Led by Dr. Amina El Ayadi and Dr. Jayson Jay, the study aims to assess RBS's safety and efficacy in wound healing phases. RBS is a key small molecule owned by Provectus, which specializes in immunotherapy medicines across various disease areas. The research could enhance the understanding of RBS's potential in treating full-thickness cutaneous wounds.
Provectus (OTCQB: PVCT) announced an exclusive worldwide license agreement with the University of Miami for a photodynamic antimicrobial therapy (PDAT) device. This collaboration will use Provectus’ rose bengal for treating bacterial, fungal, and viral infections of the eye. The company has also initiated a sponsored research program with the Ophthalmic Biophysics Center to explore rose bengal's efficacy against infectious keratitis. OBC has established its clinical proof-of-concept in treating microbial keratitis, including drug-resistant strains.
Provectus (OTCQB: PVCT) has expanded its research collaboration with Dr. Michio Kurosu at the University of Tennessee Health Science Center. This initiative focuses on evaluating pharmaceutical-grade rose bengal for its effectiveness against fungal and oral bacterial infections. The research will explore in vitro activity against various fungal strains and test susceptibility against mouth microbes. Previous studies have indicated favorable tolerability and antibacterial effectiveness of rose bengal. Provectus continues to develop immunotherapy treatments across multiple clinical areas, including oncology and dermatology.
Provectus (PVCT) announced an expansion of its sponsored research program with Dr. Aru Narendran at the University of Calgary, focusing on the treatment of pediatric leukemia using its proprietary rose bengal. The research aims to identify effective drug combinations, evaluate drug administration routes, and explore the modulation of specific pathways. Previous studies have shown promising in vitro activity of rose bengal against leukemia cells and initial in vivo effectiveness in mouse models.
Provectus (OTCQB: PVCT) has launched a new sponsored research program with Dr. Kelly Tseng from the University of Nevada, Las Vegas, aimed at studying the effects of rose bengal sodium (RBS) on vertebrate tissue regeneration. The research will utilize the African clawed frog as a model organism to evaluate key biological processes such as embryo development and wound healing. RBS is Provectus' lead compound in a class of small molecules known as halogenated xanthenes, which the company exclusively owns.